OBJECTIVES The aim of this study was to determine the incidence, predictors, and outcomes of recurrent stent thrombosis (rST).
Although there are many biological, clinical, and angiographic features that contribute to initial ST, there are limited data on the incidence, clinical presentation, and outcomes of rST (7) . Previous studies have reported incidence rates of rST of 10% to 20% during long-term follow-up (1) (2) (3) (4) (5) 8) . Two smaller studies with detailed angiographic analysis have also reported predictors of rST, including residual thrombus burden after the first ST event, a larger vessel diameter, residual dissection, and the presence of underlying malignancy (9, 10) . However, each of these studies was limited by a small number of events and differences in practice patterns. A larger, multicenter study may therefore better reflect real-world outcomes of rST.
In this study, we used a multicenter ST registry to analyze the incidence and outcomes of subjects with rST. We hypothesized that angiographic findings at the time of treatment for ST would be associated with subsequent risk of rST. (11) . Only cases of angiographic definite ST were included in the registry. For this analysis, the first presentation of ST was used as the entry criteria.
Once identified, cases were reviewed for demographic, procedural, angiographic, and in-hospital outcomes (12) . Briefly, trained abstractors and physicians reviewed each medical chart for details of presentation, medications before admission, medication compliance, procedural details of coronary angiography and intervention, and in-hospital outcomes (death, stroke, or repeat myocardial infarction). (13) . All patients in the study had grade 2 or higher thrombus to meet the definition of definite ST. In cases in which there was complete stent occlusion by thrombus, thrombus grading was also recorded after initial lesion crossing with a wire but before balloon inflation. Myocardial perfusion was scored before and after intervention from 0 to 3, as previously described (14) . Corrected Thrombolysis In Myocardial Infarction (TIMI) frame counts were also scored for each infarct-related artery (15) . A stent was defined as occurring at a bifurcation if the main vessel stent crossed a side branch $2.0 mm in diameter (provisional single stent), or if there were 2 stents present, with 1 originating in a main vessel and the second in a side branch (2-stent bifurcation). SYNTAX
(Synergy Between PCI With Taxus and Cardiac Surgery
Study) and residual SYNTAX scores were calculated as previously described (16) . All angiograms were also scored for lesion calcification, lesion severity, moderate/severe tortuosity, aneurysm, ectasia, and ulceration. A previously published risk scoring system for the prediction of ST after initial angioplasty was also calculated for patients with and without rST (17) .
The primary outcome of the study was definite/ probable rST. Secondary endpoints included angiographic definite rST, mortality, and major adverse cardiovascular events (MACE), defined as death, myocardial infarction, or stroke. The angiographic characteristics of patients are summarized in Table 2 . Half of the ST cases occurred in the left anterior descending artery (LAD), and the majority of cases had initial TIMI flow grade <3, thrombus grade of 4 or 5, and thrombus in the proximal stent. Patients who had rST develop were more 
DISCUSSION
In this study, we describe the incidence, predictors, and outcomes of rST. There are 3 major findings. Although the initial reports of ST reported inhospital and short-term mortality rates exceeding 30%, more recent reports have suggested that the in-hospital mortality rate of patients presenting to the catheterization lab with ST is 5% to 8%, with a Our finding that bifurcation ST and a larger proximal reference vessel diameter were independent predictors of rST may help provide additional risk stratification by identifying the patients at highest risk of rST. We previously reported that ST at a coronary bifurcation is associated with an increased risk of both short-and long-term MACE (18) . Two major mechanisms likely account for an increased rate of rST among patients with coronary bifurcation ST.
First, ST at a bifurcation is associated with a larger infarct, with subsequent increased risk of congestive heart failure and left ventricular remodeling, which may lead to a higher risk of subsequent thrombosis (19) . This larger infarct size may also predispose to greater microvascular injury and subsequent poor stent outflow with a greater risk of rST. Second, exposed stent struts and an altered neocarina may provide a continued nidus for thrombosis (20) .
Compared with bifurcation ST, the mechanisms relating a larger proximal reference vessel diameter to rST are uncertain. It is possible that a larger reference diameter is a proxy for greater thrombus burden and stasis predisposing to thrombosis because larger proximal reference vessel size in the infarct-related artery has been associated with a greater risk of distal vessel embolization (21) . Interestingly, one other group who examined predictors of rST also identified proximal vessel reference diameter as a predictor of rST (9) . This finding in 2 separate cohorts suggests that proximal reference vessel diameter may be an important predictor of rST in multiple realworld populations. We also speculate that stent underexpansion or malapposition may contribute to subsequent adverse events. We previously reported these findings on the basis of intravascular ultrasound in patients with ST (22) . Therefore, careful attention to accurate vessel sizing and stent deployment may help mitigate against recurrent adverse events. On the basis of these findings, we therefore believe that intravascular ultrasound use should be strongly considered during the treatment of all initial STs.
Although this study identified important angiographic predictors of rST, other demographic and procedural factors apart from age were not significant predictors of rST. Small case series have identified a number of possible contributors to rST, including hypercoagulable states, increased platelet turnover, and rheumatological diseases (23) (24) (25) (26) . Previous studies have suggested that residual dissection and residual thrombus are also both predictors of rST (10) .
There were no cases of residual dissection; this may be in part due to the relatively higher use of intravascular ultrasound in our cohort, which can provide important mechanistic insight into the etiology of ST (22) . We also had a low rate of residual thrombus in our study, likely related to the increased use of thrombectomy at the registry sites compared with previous studies. Although definitive studies are lacking, appropriate use of intravascular ultrasound and aspiration thrombectomy during treatment of ST may help provide an optimal angiographic result and thereby minimize the contribution of residual dissection or residual thrombus to the risk of recurrent ST (27, 28) . We also found that repeat stent placement during treatment of initial ST was relatively common, exceeding 50%. Because this was a retrospective study, it is difficult to identify the reason why a new stent was implanted in each case. antiplatelet agents including ticagrelor and prasugrel, it has become frequent practice to prescribe 1 of these 2 agents (in addition to aspirin) after an initial ST.
This clinical approach is on the basis of extrapolation from clinical trial data in de novo acute coronary syndromes, in which both ticagrelor and prasugrel were associated with lower rates of ST than clopidogrel (29, 30) . Given the findings of our study, patients with bifurcation ST and/or a large reference vessel diameter should especially be considered for treatment with one of these agents after an initial ST.
Additional antithrombotic approaches could also be Fourth, we do not have data on timing from symptom onset to presentation to the hospital, and it is therefore possible that the higher mortality rate of patients with rST is related to delayed presentation.
Fifth, the study period from 2005 to 2013 reflects primarily a timeframe before frequent use of ticagrelor and prasugrel. It is possible that rates of rST will decrease with more potent antiplatelet use and with newer generation drug-eluting stents (38) (39) (40) .
Sixth, the low number of total events limits the ability to perform extensive multivariable analysis. It is possible that other predictors of rST could emerge with a larger study size. 
